Existing concepts and templates created by the regulator and professional bodies are also highlighted, such as the FCA’s ...

The report summarises that ‘firms should not have to overhaul the way they work, but complying with new expectations may mean ...

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...

Hutchmed has concluded enrolment of its multi-centre Phase II trial of fanregratinib (HMPL-453), a treatment for intrahepatic ...

With AI adoption accelerating, VDURA is setting the new standard for AI-scale data performance. The V5000 All-Flash and V5000 ...

Q4 2024 Earnings Call Transcript March 7, 2025 Oncolytics Biotech Inc. beats earnings expectations. Reported EPS is $-0.06949, expectations were $-0.08. Operator: Good morning, and welcome to ...

VDURA, an AI and high-performance computing data infrastructure company, today announced the launch of its V5000 All-Flash ...

BRACELET-1 results in HR+/HER2- metastatic breast cancer surpass expectations, providing meaningful data for a registration-enabling study Data from GOBLET in pancreatic ...

VERITAC-2 has two primary endpoints, PFS in the ITT or intention-to-treat ... As a final note, we remain on track to file an investigational new drug application this year for our KRAS G12D ...